SLGL Sol-Gel Technologies Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1684693 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY68.0%
TTM net income YoY42.1%
TTM EPS YoY42.2%
Revenue 3-yr CAGR70.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.9%
Net margin-31.6%
FCF margin1.4%
EBITDA margin-38.3%
Returns
ROE-23.7%
ROA-18.6%
ROIC (approx.)-56.3%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio4.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.05x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2020Q22020-06-30 | 2019Q22019-06-30 | 2018Q22018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17.26M | $5.43M | $594,000 | $3.52M | $928,000 | $1.13M | $7.79M | $49,000 |
| R&D expense | $4.65M | $2.44M | $5.31M | $2.38M | $6.93M | $6.45M | $11.44M | $5.82M |
| SG&A expense | $1.39M | $1.37M | $1.81M | $1.60M | $2.04M | $2.23M | $1.64M | $1.52M |
| Operating income | $11.23M | $1.62M | -$6.53M | -$463,000 | -$8.04M | -$7.55M | -$5.29M | -$7.29M |
| Net income | $11.61M | $1.98M | -$5.97M | -$134,000 | -$8.03M | -$7.07M | -$4.93M | -$6.91M |
| EPS (basic) | 4.17 | 0.71 | -0.22 | 0.01 | 0.35 | 0.31 | 0.26 | 0.36 |
| EPS (diluted) | 4.17 | 0.71 | -0.22 | 0.01 | 0.35 | 0.31 | 0.26 | 0.36 |
| Weighted avg. shares (diluted) | 2.79M | 2.79M | 27.66M | 23.13M | 23.03M | 22.92M | 18.95M | 18.95M |
| Balance sheet | ||||||||
| Cash & equivalents | $10.22M | $11.55M | $15.62M | $5.76M | $11.15M | $5.44M | $14.39M | $18.24M |
| Short-term investments | $14.05M | $14.91M | $17.86M | $9.85M | $6.83M | $40.68M | $35.52M | — |
| Receivables | $10.04M | $6.06M | $2.21M | $10.18M | $956,000 | $1.17M | $7.83M | — |
| Current assets | $36.26M | $38.28M | $51.59M | $48.48M | $41.39M | $68.69M | $58.83M | — |
| PP&E, net | $162,000 | $305,000 | $569,000 | $826,000 | $1.40M | $2.20M | $2.45M | — |
| Total assets | $39.31M | $42.01M | $55.10M | $54.98M | $46.41M | $74.63M | $63.38M | — |
| Current liabilities | $4.96M | $5.20M | $5.67M | $3.23M | $5.16M | $6.91M | $7.36M | — |
| Total liabilities | $7.42M | $7.10M | $6.81M | $4.63M | $7.16M | $9.11M | $8.64M | — |
| Shareholders' equity | $31.88M | $34.90M | $48.30M | $50.35M | $39.25M | $65.52M | $54.74M | $81.55M |
| Shares outstanding | 2.79M | 27.86M | 27.81M | 23.13M | 23.03M | 23.00M | 18.95M | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
| Stock-based compensation | $100,000 | $275,000 | $498,000 | $352,000 | $213,000 | $315,000 | — | — |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.